Non-invasive Imaging Correlates with Histological and Molecular Characteristics of an Osteosarcoma Model: Application for Early Detection and Follow-up of MDR Phenotype

A. DUTOUR1,5, D. LECLERS1, J. MONTEIL2, F. PARAF3, J.L. CHARISSOUX4, R. ROUSSEAU5 and M. RIGAUD1*

Departments of 1Medical Biochemistry, 2Nuclear Medicine, 3Pathology and, 4Orthopedic Surgery, School of Medicine, University of Limoges; 5Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France

Abstract. Background: In an orthotopic rat osteosarcoma model, histological and molecular findings were compared with the results of non-invasive imaging methods to assess disease progression at the primary site, the pattern of metastatic dissemination and the chemoresistance phenotype. Materials and Methods: Primary tumor engraftment, vascularization, growth and metastatic spread were evaluated using 18FDG tomoscintigraphy. Bone neoformation in the primary tumor and metastasis was determined using 18FNa confirmed by classical histological studies. Chemoresistance phenotype was assessed by analysis of MDR1 and MRP1 genes expression compared to 99mTc MIBI imaging. Results: 99mTc MIBI imaging correlated with the overexpression of the MDR1 and MRP1 genes. 18FDG, 18FNa and 99mTc tomoscintigraphies revealed that the pattern of vascularization, bone neoformation and hematogeneous metastatic dissemination in our animal model mimics its human counterpart. Conclusion: Multimodality, non-invasive imaging is a valid surrogate marker of histological and molecular characteristics in an orthotopic osteosarcoma model in immunocompetent rats; it allows extensive in vivo follow-up of osteosarcoma, including longitudinal analysis of chemoresistance.

Osteosarcoma is the most frequent primary malignant bone tumor in children and adolescents despite accounting for only 0.1% of all tumors in this age group (1). Although the prognosis of osteosarcoma has greatly improved over the last two decades with the addition of neoadjuvant and adjuvant chemotherapy, there is still a need for efficient therapeutic alternatives for non-responders, relapsed patients and patients with metastasis. In fact, more than 30% of patients with osteosarcoma will succumb to metastatic disease (2).

A better understanding of the biology of osteosarcoma at the molecular level has allowed new therapeutic strategies to be designed. In vitro models for the evaluation of new therapeutic modalities have been developed (3, 4), but they are of limited value since they usually fail to reproduce the complex interactions of a tumor with its microenvironment (5). Consequently, agents that have shown promising therapeutic effects in vitro often fail to do so when administered in vivo in tumor models (6, 7). Hence, new therapeutic modalities should ideally be evaluated in a relevant animal tumor model before going into human clinical trials.

An ideal osteosarcoma animal model should be syngeneic, grow at orthotopic site, have a metastatic potential and be highly reproducible. Most osteosarcoma models currently available do not meet all these criteria. Most are xenotransplants models in immunocompromised animals (8-10). Only few models are syngeneic, usually carcinogen- or radio-induced; they usually grow at heterotopic sites (11, 12). Canine osteosarcoma is a pertinent model since it is both syngeneic and orthotopic but the availability of canine agents limits the extent of this naturally occurring tumor model.

The value of the multidrug resistance genes MDR1 and MRP1 as prognostic factors has been suggested in osteosarcoma (13). The products of these two genes, Pgp for MDR1 and MRP for MRP1, belong to the ATP binding cassette superfamily of membrane transporter proteins (14, 15). Both proteins act as energy-dependent efflux pumps that convey cytotoxic drugs and radioactive markers such as
99mTc Sestamibi (99mTc MIBI) out of tumor cells (16). In our institution, we have an orthotopic osteosarcoma model established in immunocompetent rats. We have previously used this model to evaluate the therapeutic efficiency of suicide-gene and antiangiogenic-gene therapy approaches (6, 17, 18). In this study, we described the morphological, histological and molecular characteristics of this model, using conventional analyses (immunohistology and molecular methods) and non-invasive imaging studies: we evaluated the possibility of using multimodality-imaging techniques to analyse, in an in vivo and real-time non-invasive manner, the evolution of a primary tumor, apparition of metastases, the determination and longitudinal evolution of chemoresistance phenotype. If we can show that multimodality-imaging studies adequately correlate with the conventional, more invasive analysis methods, this would allow for design of preclinical therapeutic approaches that require fewer animals given that the follow-up of tumor response and the evolution of chemoresistance phenotype could be done without the need to euthanize animals.

Materials and Methods

Tumor model and treatment. All surgical procedures and care given to animals were performed according to institutional and national guidelines. Surgical procedures were conducted under general anesthesia with isoflurane/oxygen (2.5%/2.5%) dispensed by an anaesthesia apparatus (Minerve, Esternay, France). Three independent series of 21- to 28-day-old Sprague-Dawley rats (Centre d’élevage Depré, St Doulchard, France) were used in this study. The orthotopic osteosarcoma used was initially established by local injection of colloidal radioactive 144Cerium (19) and a transplantable tumor was obtained from this radio-induced tumor (20). Small fragments (50 mm3) sampled from the hyperproliferative osteogenic area were grafted in a paratibial position into the left posterior leg of rats after periostic abrasion. When tumor 18FDG uptake reached 4% of the whole body fixation, the animals were randomly divided into two groups of 10 animals each, one control and one methotrexate-treated group. The chemotherapy-treated group received a weekly intraperitoneal injection of methotrexate at a dose of 0.25 mg/kg (Sanofi-Aventis, Paris, France) over a period of 4 weeks. The control group received at the same frequency intraperitoneal injections of physiological serum. The study was conducted over 35 days. Tumors were measured twice weekly throughout the study, and the volume calculated using the formula established by Carlson (V=0.5x a x b2 where a is the largest diameter measured and b the smallest) (21). All animals were euthanized if they showed any sign of distress or when the orthotopic tumor reached 20±2 cm3. At the time of necropsy, tumors, lungs, liver, heart and skeletal muscle were collected for RT-PCR assays and/or histological examinations.

RT-PCR for the determination of multidrug-resistance genes expression. Total RNA was extracted from disrupted tissues (primary tumor, lung, lung metastases, skeletal muscle, cardiac muscle, liver) using an RNAeasy® mini kit, (Qiagen, Courtaboeuf, France) according to the manufacturer’s instructions. cDNA amplification was obtained by RT-PCR on 5 ìg of RNA using the Omniscript® RT kit (Qiagen), specific sets of primers for each gene and the AmpliTaqGold® Taq DNA polymerase (Applied Biosystems, Foster City, CA, USA). β-actin was used as a control to which the expression of MDR1 and MRP1 genes was normalized. Primer sequences and length of PCR products are shown in Table I (22, 23). PCR products were separated by electrophoresis on a 1% agarose gel and visualized under UV light in the presence of ethidium bromide. Semiquantitative gene-expression analyses were performed using a Kodak Image Station and corresponding software (Kodak, New Haven, CT, USA).

Pathology. Tumors and lungs were fixed in 10% formalin. Paraffin-embedded tumor sections (8 µm) were stained using hematoxylin-eosin saffron (HES). Triple immunohistochemical staining for endothelial and apoptotic cell detection was performed on frozen sections blocked with 5% goat serum (Chemicon, Temecula, CA, USA). Endothelial cells were stained with RECA-1 primary antibody (1/400; Serotec, Oxford, UK) and Cy3-goat anti-mouse IgG as secondary antibody (1/400; Jackson Lab).

### Table I. Primers and PCR-amplified fragments for analysis of MDR1 and MRP1 expression by RT-PCR.

<table>
<thead>
<tr>
<th>Primers</th>
<th>Size of amplified fragment</th>
<th>Sequence amplified</th>
<th>Accession number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fw: CGCCATGGATGACGATATCGC</td>
<td>472 bp</td>
<td>Beta Actin</td>
<td>NM 031144 (23)</td>
</tr>
<tr>
<td>Rv: CTCCGGAGTCATACATGCG</td>
<td>394 pb</td>
<td>MRP 1</td>
<td>X 96394 (22)</td>
</tr>
<tr>
<td>Tm: 56°C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fw: CGGCTTTGGTGAAACTGAT</td>
<td>440 bp</td>
<td>MDR 1a</td>
<td>S66618 (23)</td>
</tr>
<tr>
<td>Rv: AGGCTCTCGTGGCTCTAT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tm: 53°C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fw: GACAGAAACAGAGGATCGC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rv: CCGCTTCTGATCATGTCGCC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tm: 55°C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fw: GAAATAAATCGTATGATCCCCAAAG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rv: GGTTATCGTCTGGCTCTTGA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tm: 56°C</td>
<td>326 bp</td>
<td>MDR 1b</td>
<td>S66618 (23)</td>
</tr>
</tbody>
</table>

Fw: forward primer, Rv: reverse primer, Tm: melting temperature.
Immunoresearch, West Grove, PA, USA). Apoptotic cells were detected by terminal deoxynucleotidal transferase-mediated (dUTP) biotin nick end labeling (TUNEL) (In Situ Cell Death Detection Kit, Roche, Mannheim, Germany) and 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma Aldrich, St Louis, MO, USA) (1 µg/mL in PBS).

Imaging studies. Imaging studies were performed weekly on all animals. In vivo functional and metabolic imaging studies were performed using 18FDG (fluorodeoxyglucose) coincidence detection emission tomography (18FDG CDET) and technetium 99m methoxyisobutylisonitrile (99mTc-MIBI) scintigraphy. The 99mTc-MIBI scintigraphy was performed 48 h after 18FDG CDET.

After fasting for 6 h, animals were injected intravenously with 92 MBq/kg of 18FDG (Flucis, Shering/Cis-bio International, Gif-sur-Yvette, France). Tomographies were performed 5 h after the intravenous injection using a double-head gamma camera (Axis, Philips Medical Systems, WA, USA). Following a 30-minute bidimensional acquisition consisting of 30 steps every 6°, data were processed without attenuation correction and images were reconstructed using an iterative method (EMML: 20 iterations). 18FDG uptake was defined as the ratio between the tumor radioactivity within the tumor mass compared to the whole body total radioactivity detected in the 5-cm thickness coronal slice (tumor uptake= tumor radioactivity/total radioactivity). Acquisition was performed immediately after the intravenous injection of 30 MBq/kg of 99mTc-MIBI. Thirty-minute imaging static acquisition was obtained from anesthetized rats laying on the gamma camera (DSX, Sopha Medical, France). Tumor 99mTc-MIBI uptake index was defined as the ratio between tumor and whole body radioactivity. Acquisition was performed 5 h after an intravenous injection of 370 MBq/kg of 18FNa. Sixty-minute image acquisition was conducted using a gamma camera similarly to 18FDG acquisition.

Statistical analysis. All data are presented as means±SEM. Differences from the mean were tested for significance by means of the Student’s t-test using Statview Software. The level of statistical significance was set at p<0.05.

Results

18FDG uptake (18FDG CDET) correlates with primary tumor growth. Tumor engraftment at the primary site of implantation occurred in more than 95% of the animals. The primary tumor progressed rapidly from the time of implantation: after seven days, a primary tumor could readily be detected by physical palpation in 98% of transplanted animals. The mean tumor volume significantly increased from 0.23±0.05 cm^3 at day 7 to 20.5±2.263 cm^3 at day 35 (p<0.01) (Figure 1A). These physical findings correlated with 18FDG uptake (Figure 1A and 1B) with uptake as low as 3±1% at day 7 if the tumor was palpable up to 36±7% of whole body fixation at day 35 (p<0.01) (Figure 1B) with a mean tumor volume measured at 20.5 cm^3 (range from 17.5 to 24.25 cm^3). 18FDG uptake in the controlateral paw did not change throughout the study.

18FNa uptake corroborates osteogenesis of the primary tumor. Preferential uptake of 18FNa in newly mineralized bones correlates with bone formation. 18FNa imaging performed 4 weeks after tumor implantation revealed heterogeneity of primary tumors with differentially stained areas, the center of the tumor appearing unstained while an intense uptake was observed at its periphery (Figure 2A). These scintigraphic findings were confirmed histologically, the periphery of the tumor appearing mineralized with signs of hyperproliferation: high cell density, increased mitotic index, bulky irregular nuclei with frequent nucleoli (Figure 2B). In sharp contrast, the central portion of the tumor often appeared clearly necrotic with numerous microcalcifications and areas of viable proliferating tumor cells forming a vessel-centered ring (Figure 2C).

Vascular spread is the preferred route of metastatic dissemination. Endothelial cells staining with RECA-1 antibody revealed dense vascularization consisting of normal and irregular vessels forming clusters of high vascular density whereas other parts of the tumor lacked any vessels (Figure 3A). The vascular density was the highest at the hyperproliferative periphery of the tumors. This anarchic vascular structure is typical of osteosarcoma in humans, particularly in highly aggressive tumors. Only few apoptotic tumor cells were detected by TUNEL staining confirming the aggressivity of the tumor (Figure 3B).

18FDG uptake (18FDG CDET) reveals early metastatic spread. Pulmonary metastases (≥4 mm in diameter) were detected by 18FDG as early as 3 weeks after tumor implantation (Figure 1B). The presence of these metastases was confirmed by histological examination of euthanazed animals 24 hours after imaging. Five weeks after tumor implantation, all the animals had lung metastases, many of them being macroscopically visible on pathological examination reaching up to 1 cm in diameter (Figure 4A). Histologically, metastases consisted of densely packed large malignant mesenchymal cells similar to those seen in the primary tumor (Figure 4). In the largest metastases, necrotic areas representing 10% of the tumor could be found in the middle of the metastases. Metastases were also detected by 18FNa imaging, (Figure 2A); an intense uptake of this radionucleide at the lung site correlated with the formation of osteoid at the periphery of these metastases, as confirmed by classical HES staining (Figure 4A). These observations confirmed the aggressiveness of the metastases spreading from the primary tumor, a characteristic also observed in human osteosarcoma.

99mTc-MIBI uptake is related to the multi-drug resistance phenotype. 99mTc-MIBI scans were performed on a weekly basis over the study, the first two days after tumor first
detection by $^{18}$FDG CDET. $^{99m}$Tc-MIBI scans did not reveal any increased uptake of the radionucleide at the primary tumor site compared to the controlateral healthy paw (Figure 5A). This absence of $^{99m}$Tc-MIBI uptake was maintained over time (Figure 5A) and was due to the rejection of the tracer by the transporter proteins, Pgp and MRP1. The expression of these proteins by the tumor cells were confirmed by RT-PCR.

RT-PCR on organs 24 h after $^{99m}$Tc-MIBI imaging revealed variable MDR1 and MRP1 gene expression with levels ranging from undetectable to high (Figure 5B). MDR1 isoforms showed selective tissue distribution with the MDR1a and MDR1b isoforms being expressed in the heart, primary tumor and lung metastases (Figure 5B) When normalized to $\beta$-actin expression, MDR1 and MRP1 gene expression appeared overexpressed in the primary tumor as well as lung metastases (a 2.1-fold expression of the MDR1 isoforms and a 1.8-fold overexpression of MRP1, respectively) thus correlating with the absence of tumor fixation of $^{99m}$Tc MIBI. As soon as the tumor could be detected, expression of both MDR1 isoforms and MRP1 was evident in the tumor. This observation shows that the
chemoresistant phenotype of the rat osteosarcoma model is not induced by chemotherapy.

Whereas the expression of MDR1 isoforms and MRP1 by tumor cells did not change over time (Figure 5A, B), it was altered by chemotherapy. The group of rats treated by 4 courses of methotrexate chemotherapy presented an increase in MDR1 and MRP1 tumor expression as shown by RT-PCR. A 2.4-fold expression of MDR1a, 2.6 fold of MDR1b and 1.9-fold of MRP1 were observed (Figure 5D) in comparison to the expression level of these genes at the same time point in the untreated group (Figure 5B). This increase is characterized by the same absence of tumor uptake of 99mTc MIBI that was observed over time (Figure 5C). It is of note that methotrexate did not significantly inhibit primary tumor growth as assessed by tumor volume evolution (Figure 6), the mean tumor volume of the treated group reaching 21.8 cm³ whereas the mean tumor volume of the control group was 21 cm³ ($p>0.05$).

**Discussion**

Despite the improvements in chemotherapeutic regimens over the last two decades, the 5-year survival rate of osteosarcoma patients has remained stable (55%-70%) (24). This clearly shows that there is a need for new therapeutic approaches for osteosarcoma treatment. To assess new strategies, relevant preclinical animal models and clinically relevant follow-up methods are needed. Using non-invasive imaging methods, we describe an orthotopic rat osteosarcoma model mimicking the human one, hereby showing the validity of these methods in following-up tumor evolution and its histological and phenotypic features.

While several animal models of osteosarcoma have been developed over the years, few of them are tumorigenic and metastatic (25-27). Among the remaining, even fewer are established in immunocompetent animals (28, 29); to our knowledge, only two other models show these characteristics (28). Here we described the characteristics of a highly reproducible rat osteosarcoma model that meets most, if not all, of the requirements of a preclinical model: reproducibility, primary tumor growth, metastatic potential, tumor histological and phenotypic features. Similarly to human osteosarcoma, our syngeneic orthotopic osteosarcoma model in immunocompetent rats showed evidence of bone invasion, osteoid formation and high tumor angiogenesis, all indicators of tumor malignancy predictive of metastatic potential (30, 31) and consistent with hematogeneous spreading similar to human osteosarcoma (1). The high growth rate at the primary site resulted in morbidity as early as 28 days following the implantation of tumor fragments. As evidenced by 18F FDG imaging, the primary tumor had a high glucose metabolism that correlated with rapid growth, invasiveness and metastatic spread to the lungs. The imaging methods, confirmed by classical histological and molecular analyses, enabled us to establish that the pulmonary metastases present the same phenotypic and histological characteristics as the primary tumor cells, showing that osteosarcoma cells are as aggressive in the primary tumor as they are in the lung metastases.

RT-PCR, corroborated by 99mTc-MIBI imaging, established that MDR1 and MRP1 were overexpressed in the primary tumor and in the pulmonary metastases. Overexpression of these genes is associated, in different tumors, with resistance to standard chemotherapy and excretion of radiotracer 99mTc MIBI, two characteristics presented by our model. Multidrug resistance associated with overexpression of MDR1 and MRP1 genes is a major problem in the treatment of osteosarcoma (16, 32, 33). Moreover, we showed that primary tumor expression of MDR1 and MRP1 increases under chemotherapeutic treatment, a fact often found in human tumors (34). In patients with osteosarcoma, MDR1 overexpression at diagnosis correlates with resistance to chemotherapy and is an important adverse prognostic factor (35). We clearly show that 99mTc MIBI imaging has a role in the early detection of MDR
The phenotype of osteosarcoma and could therefore be useful for the early identification of non-responders, or the evaluation of chemosensitisers in vivo in preclinical animal models and ultimately in patients (16, 36, 37).

The originality of our study resides in the use of non-invasive imaging methods to monitor disease progression and chemoresistance in vivo without the classical limitations of animal euthanasia to analyze tumor histology and...
determine metastasis emergence. The correlation between tumor volume and tumor $^{18}$FDG uptake has been described for several tumor types (38) and reinforces the validity of $^{18}$FDG tomoscintigraphy as an early, non-invasive metabolic predictor for tumor response before any gross morphological changes occur (18, 38-40). These findings, along with our current results, confirm our previous study in rats where we showed that osteosarcoma regression can be detected by $^{18}$FDG before any morphological changes could be noticed and that $^{18}$FDG uptake is the most significantly negative prognosis factor (18, 38). $^{18}$FDG is incorporated only into viable cells. Hence, it can also distinguish between necrotic and viable areas and may represent an important prognostic marker in patients with osteosarcoma undergoing neoadjuvant chemotherapy (41). We have shown that $^{18}$FNa imaging also allows the detection of osteoid formation in the primary tumor as well as in metastases and may provide valuable morphologic and prognostic information.

In this study, we characterize a preclinical model of osteosarcoma using clear-cut in vivo imaging techniques. These techniques ($^{18}$FDG and $^{99m}$Tc scintigraphies), which have been validated in patients (40, 41), provide a reliable, non-invasive, functional account of the tumor's behavior. Conversely to more conventional morphological methods, these techniques in our syngeneic orthotopic osteosarcoma model closely mimic its human counterpart, require fewer animals and can be repeated several times without major discomfort to the animal. Taken together our results show that this preclinical osteosarcoma model and the follow-up methods used in this study are relevant for the preclinical study of new drugs and innovative therapies.

**Acknowledgements**

This work was supported by a grant from La Ligue Nationale contre le Cancer (comité de la Haute Vienne). The authors would like to thank Jacques Demonent for excellent animal care.

**References**


Received May 2, 2007
Revised July 25, 2007
Accepted August 17, 2007